Tax exemption on specified medical drugs reduces state GST rates for listed COVID therapeutics for a temporary period. Exempts specified pharmaceutical goods from state tax in excess of the rates specified in the notification, referencing tariff items in the First Schedule to the Customs Tariff Act; Tocilizumab and Amphotericin B are subject to nil state tax, while Remdesivir, Heparin, Itolizumab, Posaconazole, Infliximab, Bamlanivimab & Etesevimab, Casirivimab & Imdevimab, 2 Deoxy D Glucose and Favipiravir are subject to a reduced state tax rate; the exemption operates for the temporary period from October through December 2021.
Cases where this provision is explicitly mentioned in the judgment/order text; may not be exhaustive. To view the complete list of cases mentioning this section, Click here.
Provisions expressly mentioned in the judgment/order text.
Tax exemption on specified medical drugs reduces state GST rates for listed COVID therapeutics for a temporary period.
Exempts specified pharmaceutical goods from state tax in excess of the rates specified in the notification, referencing tariff items in the First Schedule to the Customs Tariff Act; Tocilizumab and Amphotericin B are subject to nil state tax, while Remdesivir, Heparin, Itolizumab, Posaconazole, Infliximab, Bamlanivimab & Etesevimab, Casirivimab & Imdevimab, 2 Deoxy D Glucose and Favipiravir are subject to a reduced state tax rate; the exemption operates for the temporary period from October through December 2021.
Full Summary is available for active users!
Note: It is a system-generated summary and is for quick reference only.
TaxTMI 
of 
TaxTMI 
